Coherence Neuro Raises $45M Co-Led by Founders Fund and OpenAI to Treat Brain Cancer with Bioelectronic AI

Good morning, HealthTech insiders. The traditional boundary separating pure software from physical biological intervention is disintegrating at an astonishing rate. When AI moves beyond recommending static treatments to directly modulating tumor electrophysiology inside the human brain or operating industrial robotic arms inside sterile cleanrooms, the nature of healthcare value creation fundamentally transforms.

Today's briefing explores this physical computing frontier. Coherence Neuro secured $45 million co-led by Founders Fund and the OpenAI Startup Fund to deploy closed-loop brain implants that track and treat cancer with electrical fields. Meanwhile, Multiply Labs raised $75 million backed by Patrick Soon-Shiong and AstraZeneca to automate cell and gene therapy manufacturing, while Baba landed $40 million to deploy long-horizon autonomous AI agents across Medicare care coordination.

In today's Signal:

• Bioelectronic Cancer Therapy: Coherence Neuro raises $45M from Founders Fund and OpenAI to treat glioblastoma with real-time electrical implants.

• Automating Cell Therapy Factories: Multiply Labs closes $75M Series B with AstraZeneca and NantWorks to cut CAR-T manufacturing costs by 74%.

• Autonomous Medicare AI Agents: Baba secures $40M Series A from FirstMark and CVS Health Ventures to execute multi-week clinical care coordination.

• Capital Pattern Analysis: Why healthcare investors are heavily backing physical AI infrastructure and industrial automation layers.

In partnership with

Two days of free email tactics, starting Nov 12

GURU kicks off Nov 12. Join the 29,000+ marketers who showed up last year, 100% free and virtual.

GURU Conference, powered by Constant Contact, is back November 12-13. It's 100% virtual and 100% free, and it's packed with tactics you can use right away on newsletters, deliverability, design trends, AI, and what NOT to do with email.

What to expect:

• Speakers including Molly Ringwald, Dan Levy, Amy Porterfield, Frank Vella + more

• Sessions from world-class marketers at top brands

• Networking every day

• DJs, world-record breaking, and an alarming amount of rom-com fun!

Last year, 29,000+ marketers joined us. This year is even bigger, and spots are limited.

Save my free spot

FRONTIER AI & BIOELECTRONIC ONCOLOGY
1. Coherence Neuro Raises $45M Co-Led by Founders Fund and OpenAI to Treat Brain Cancer with Bioelectronic AI

San Francisco-based Coherence Neuro announced a $45 million Series A funding round co-led by Founders Fund and the OpenAI Startup Fund, joined by Lux Capital, 8VC, Ahren, and Neuralink head neurosurgeon Matthew MacDougall, to advance closed-loop bioelectronic implants for oncology.

The details:

• Electrical Tumor Biomarkers: Coherence has decoded electrical field oscillations in peritumoral brain tissue that correlate with active glioblastoma growth, enabling early detection of micro-recurrences.

• First-In-Human Data: Completed initial clinical testing across three patients at the Royal Melbourne Hospital, recording real-time electrical signals via thin-film CIPHER electrode arrays during tumor resections.

• Closed-Loop Therapeutics: The implant delivers localized, non-thermal electrical fields that disrupt mitotic spindle formation, halting cancer cell division while preserving healthy neurons.

The Signal: OpenAI's participation in Coherence Neuro marks a pivotal shift for frontier AI labs from digital software assistants into bio-integrated hardware therapeutics. By treating cancer as an electrophysiological signaling disorder rather than purely a genetic mutation, closed-loop neural implants create a continuous, adaptive therapeutic layer that traditional systemic chemotherapies cannot match.

BIOMANUFACTURING ROBOTICS & CELL THERAPY
2. Multiply Labs Lands $75M Series B Led by Patrick Soon-Shiong to Automate Cell and Gene Therapy Manufacturing

Robotics pioneer Multiply Labs raised a $75 million Series B led by Dr. Patrick Soon-Shiong and NantWorks, with participation from AstraZeneca, Lingotto, Teradyne, Casdin Capital, and Lux Capital, bringing total equity funding past $100 million.

The details:

• Industrial Robotic Clusters: Standardized robotic pods execute sterile liquid handling, viral vector transduction, and cell culture for CAR-T and mRNA therapies inside existing cleanrooms.

• Economic Transformation: Eliminates manual cleanroom technician bottlenecks, achieving a verified 74% reduction in cost-per-dose and up to 100x throughput expansion.

• Commercial Adoption: Global pharmaceutical leaders including AstraZeneca and Legend Biotech are deploying Multiply's robotic clusters to manufacture commercial cell therapy batches.

The Signal: The commercial bottleneck for curative CAR-T and personalized cancer vaccines has shifted from biology to manufacturing logistics. With skilled cleanroom labor scarce and batch costs exceeding $300,000, robotic automation turns cell therapy into a scalable industrial product, lowering prices and unlocking broad payer reimbursement.

AUTONOMOUS AI AGENTS & VALUE-BASED CARE
3. Baba Secures $40M Series A from FirstMark and CVS Health to Deploy Autonomous AI Care Teams for Medicare

New York-based applied AI company Baba raised a $40 million Series A led by FirstMark Capital, with participation from CVS Health Ventures, value-based care fund Valtruis, and returning backer General Catalyst.

The details:

• Hybrid Care Coordination: Pairs dedicated human clinical social workers and therapists with autonomous AI agents that resolve complex administrative tasks across Medicare and Medicaid cohorts.

• Long-Horizon Execution: Autonomous agents navigate complex insurance prior authorization appeals, resolve billing claim disputes over phone calls, and coordinate post-hospital discharge care.

• BabaBench Release: Published BabaBench on arXiv and at NeurIPS, establishing the first standardized open benchmark for testing AI agent reliability on multi-week patient advocacy tasks.

The Signal: Healthcare AI is evolving from single-turn documentation scribes into persistent, goal-driven agents capable of executing multi-week administrative workflows. Backing from CVS Health Ventures and Valtruis proves that value-based health plans view autonomous agents as the only viable mechanism to scale high-touch care coordination across aging Medicare populations.

👀 WHAT WE'RE WATCHING NEXT

• Coherence Neuro FDA Breakthrough Designation: Whether the FDA grants Breakthrough Device status for the CIPHER implant, establishing an accelerated pathway for clinical glioblastoma trials in early 2027.

• Multiply Labs Biomanufacturing Regulatory Submissions: How the FDA evaluates chemistry, manufacturing, and controls (CMC) documentation generated by automated robotic pods for commercial CAR-T batches.

• Payer Prior Auth Automation Rules: How health plans respond to autonomous AI agents (like Baba) conducting real-time phone appeals and claims dispute negotiations against algorithmic payer denial engines.

💰 FOLLOW THE MONEY

The deals:

• Multiply Labs: $75 Million Series B led by Dr. Patrick Soon-Shiong / NantWorks with AstraZeneca and Teradyne to automate cell and gene therapy manufacturing.

• Coherence Neuro: $45 Million Series A co-led by Founders Fund and OpenAI Startup Fund with Lux Capital to develop closed-loop brain cancer electrical implants.

• Baba: $40 Million Series A led by FirstMark Capital with CVS Health Ventures and Valtruis to deploy autonomous AI agents across Medicare care coordination.

The pattern: Capital allocation in late October 2026 is aggressively rewarding industrial-grade automation and physical computing infrastructure across healthcare. Venture syndicates are prioritizing platforms that eliminate physical bottlenecks, from automating sterile cell therapy production lines (Multiply Labs) and deploying bioelectronic implants that disrupt tumor electrophysiology (Coherence Neuro) to executing multi-week agentic insurance workflows (Baba).

📆 UPCOMING HEALTHTECH EVENTS

• HLTH 2026 Global Convening | November 15-18, 2026 | Las Vegas, NV • The premier annual gathering of digital health leaders, payers, health systems, and healthtech investors.

• ARPA-H SURPASS National Proposers Day | November 6, 2026 | Austin, TX & Virtual • Federal briefing on multi-million-dollar ARPA-H contracts for autonomous clinical trial platforms.

• RSNA 2026 (Radiological Society of North America) | November 29 - December 3, 2026 | Chicago, IL • The world's largest medical imaging conference showcasing diagnostic AI, ultrasound robotics, and multimodal radiology models.

🛠️ Trending HealthTech AI Tools

• CIPHER Bioelectronic Array: Thin-film brain implant that continuously records tumor electrical biomarkers and delivers targeted anti-mitotic electrical fields.

• Multiply Biomanufacturing Pods: Standardized robotic clusters automating liquid handling and cell incubation for CAR-T and mRNA therapies with 74% cost reduction.

• BabaBench Agent Framework: Open benchmark framework for evaluating autonomous AI agents on long-horizon healthcare advocacy, prior authorizations, and appeals.

🛠️ Trending HealthTech AI Startups

• Coherence Neuro: Closed-loop bioelectronic cancer therapeutics startup backing brain implants for glioblastoma ($45M Series A).

• Multiply Labs: Industrial biomanufacturing robotics company automating cell and gene therapy production ($75M Series B).

• Baba: Autonomous AI care coordination company pairing AI agents with clinical care teams for Medicare/Medicaid ($40M Series A).

DECISION INTELLIGENCE

Highlights: Deep Dives & Industry Reports

• Bioelectronic Oncology: The Strategic Science of Coherence Neuro's $45M Brain Cancer Bet (Electrophysiological tumor signaling, closed-loop neural implants, and OpenAI's hardware thesis).

• Industrializing Cell and Gene Therapy: The Economics of Multiply Labs' $75M Robotic Cleanroom Clusters (CAR-T cost-per-dose compression, cleanroom labor shortages, and biopharma adoption).

• Long-Horizon Agentic Workflows in Medicare: Baba and the Economics of Autonomous Care Coordination (BabaBench evaluation, prior auth dispute automation, and value-based health plan ROI).

That's it for today!

The unifying theme connecting today's bioelectronic oncology breakthroughs, robotic cell therapy factories, and autonomous care coordination agents is that healthcare technology is maturing from passive observation into active, closed-loop intervention.

When clinical intelligence operates directly inside the physical world, whether at the cellular level in a cleanroom or inside the peritumoral brain margin, the velocity of medical progress compounds exponentially. How is your organization preparing for the convergence of physical robotics, bioelectronics, and autonomous agents?

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.